iM4TB, through its participation in ERA4TB – a European Union’s Horizon 2020 research and innovation program – is supporting initial development of a long-acting injectable (LAI) version of Macozinone, a potential new therapy for tuberculosis (TB)
LAI Macozinone could help address some of the biggest challenges in TB treatment: facilitating access, improving patient adherence even after symptoms subside, and lowering the risk of drug resistance
TB remains one of the deadliest diseases in history, still causes over 1.2 million deaths every year
iM4TB, Innovation Medicines for Tuberculosis, is a Swiss non-profit foundation dedicated to accelerating affordable TB treatments, backed by world-class partners like the Gates Foundation, and active in global collaborations especially in ERA4TB alongside leading organizations such as GSK, J&J, Evotec, TB Alliance, Universidad Carlos III de Madrid and the Pasteur Institute
Read the full press release here.
For more TB updates, check out the TB CAB Weekly Newsletter (Issue #14, 25 April 2025).
The newsletter is brought to you by the Global TB Community Advisory Board (TB CAB) with the support of Treatment Action Group (TAG) and EATG. Subscribe to the newsletter here.
Source : Medincell
Related HIV and Co-Infections News
-
The Lancet Global Health: Untangling the complex relationship between HIV-exposure and TB in children: A narrative review
-
Research Centre Borstel: Long-term cure rates for multidrug-resistant TB much better than expected
-
Liverpool School of Tropical Medicine: New pooled testing toolkit to help expand TB diagnosis to ‘missed millions’
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.